SK283817B6 - Nosič založený na lipide, farmaceutická kompozícia s jeho obsahom a jeho použitie - Google Patents

Nosič založený na lipide, farmaceutická kompozícia s jeho obsahom a jeho použitie Download PDF

Info

Publication number: SK283817B6
Authority: SK; Slovakia
Prior art keywords: lipid; carrier; cholesterol; lipids; glycerolipid
Prior art date: 1996-10-15

Application number

SK493-99A

Other languages

English (en)

Slovak (sk)

Other versions

SK49399A3 (en

Inventor

Walter Perkins

Eric Mayhew

J. Craig Franklin

Andrew S. Janoff

Original Assignee

The Liposome Company, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-15

Filing date

1997-10-15

Publication date

2004-02-03

1997-10-15 Application filed by The Liposome Company, Inc. filed Critical The Liposome Company, Inc.

1999-11-08 Publication of SK49399A3 publication Critical patent/SK49399A3/sk

2004-02-03 Publication of SK283817B6 publication Critical patent/SK283817B6/sk

Links

150000002632 lipids Chemical class 0.000 title claims abstract description 172
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
239000000969 carrier Substances 0.000 title abstract description 11
206010028980 Neoplasm Diseases 0.000 claims abstract description 20
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 97
239000002502 liposome Substances 0.000 claims description 71
235000012000 cholesterol Nutrition 0.000 claims description 49
150000002313 glycerolipids Chemical class 0.000 claims description 27
229930182558 Sterol Natural products 0.000 claims description 20
235000003702 sterols Nutrition 0.000 claims description 20
230000000295 complement effect Effects 0.000 claims description 19
-1 anionic sterol Chemical class 0.000 claims description 18
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
230000007935 neutral effect Effects 0.000 claims description 12
150000003432 sterols Chemical class 0.000 claims description 11
BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims description 8
BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical group C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 3
230000037396 body weight Effects 0.000 claims description 3
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
239000002691 unilamellar liposome Substances 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
239000011593 sulfur Substances 0.000 claims 1
238000010348 incorporation Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 description 29
210000004027 cell Anatomy 0.000 description 25
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 21
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 18
238000000034 method Methods 0.000 description 14
150000002430 hydrocarbons Chemical group 0.000 description 12
206010018910 Haemolysis Diseases 0.000 description 11
230000008588 hemolysis Effects 0.000 description 11
229930195733 hydrocarbon Natural products 0.000 description 10
230000009467 reduction Effects 0.000 description 10
MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 9
210000003743 erythrocyte Anatomy 0.000 description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
239000002356 single layer Substances 0.000 description 9
238000005481 NMR spectroscopy Methods 0.000 description 8
239000012867 bioactive agent Substances 0.000 description 8
201000011510 cancer Diseases 0.000 description 8
230000002949 hemolytic effect Effects 0.000 description 8
239000000693 micelle Substances 0.000 description 8
241000446313 Lamella Species 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 7
230000002209 hydrophobic effect Effects 0.000 description 7
239000012528 membrane Substances 0.000 description 7
239000011148 porous material Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
150000002170 ethers Chemical class 0.000 description 6
230000036210 malignancy Effects 0.000 description 6
239000012071 phase Substances 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
239000004215 Carbon black (E152) Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000006378 damage Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000001125 extrusion Methods 0.000 description 5
238000004806 packaging method and process Methods 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000714177 Murine leukemia virus Species 0.000 description 4
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
125000002252 acyl group Chemical group 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
238000009826 distribution Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000010408 film Substances 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
108010003541 Platelet Activating Factor Proteins 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000018044 dehydration Effects 0.000 description 3
238000006297 dehydration reaction Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000012856 packing Methods 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
239000011574 phosphorus Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
229960005536 Alkyl-lysophospholipid Drugs 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000118 anti-neoplastic effect Effects 0.000 description 2
230000002141 anti-parasite Effects 0.000 description 2
230000009876 antimalignant effect Effects 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
239000003096 antiparasitic agent Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002296 dynamic light scattering Methods 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
125000003473 lipid group Chemical group 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000008520 organization Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
229940067605 phosphatidylethanolamines Drugs 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000000527 sonication Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
ASWBNKHCZGQVJV-HSZRJFAPSA-N 1-hexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-HSZRJFAPSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
101100006310 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chol-1 gene Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000145525 Spinach latent virus Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
OEWZGBLJCYAMEG-UHFFFAOYSA-N [2-(octadecoxymethyl)oxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC1(COP([O-])(=O)OCC[N+](C)(C)C)CCCO1 OEWZGBLJCYAMEG-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000010441 alabaster Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001399 anti-metabolic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000007952 growth promoter Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002637 mydriatic agent Substances 0.000 description 1
230000002911 mydriatic effect Effects 0.000 description 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000008188 pellet Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229950004354 phosphorylcholine Drugs 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000010926 purge Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK493-99A 1996-10-15 1997-10-15 Nosič založený na lipide, farmaceutická kompozícia s jeho obsahom a jeho použitie SK283817B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/720,997 US5932242A (en)	1996-10-15	1996-10-15	Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof
PCT/US1997/018546 WO1998016200A1 (en)	1996-10-15	1997-10-15	Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof

Publications (2)

Publication Number	Publication Date
SK49399A3 SK49399A3 (en)	1999-11-08
SK283817B6 true SK283817B6 (sk)	2004-02-03

Family

ID=24896093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK493-99A SK283817B6 (sk)	1996-10-15	1997-10-15	Nosič založený na lipide, farmaceutická kompozícia s jeho obsahom a jeho použitie

Country Status (17)

Country	Link
US (2)	US5932242A (pt)
EP (1)	EP0966266A4 (pt)
JP (1)	JP2001502332A (pt)
KR (1)	KR100512689B1 (pt)
CN (1)	CN1088582C (pt)
AU (1)	AU722092B2 (pt)
BR (1)	BR9712329A (pt)
CA (1)	CA2268841A1 (pt)
CZ (1)	CZ131799A3 (pt)
HU (1)	HUP0000523A3 (pt)
IL (1)	IL129473A0 (pt)
NO (1)	NO991770L (pt)
NZ (1)	NZ335125A (pt)
PL (1)	PL190711B1 (pt)
SK (1)	SK283817B6 (pt)
TR (1)	TR199900799T2 (pt)
WO (1)	WO1998016200A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6667053B1 (en)	1996-02-16	2003-12-23	Elan Pharmaceuticals, Inc.	D and L etherlipid stereoisomers and liposomes
DE19829448A1 (de) *	1998-07-01	2000-10-12	Medmark Pharma Gmbh	1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
US20060116354A1 (en) *	2003-01-09	2006-06-01	Perkins Walter R	Antineoplastic ether lipid compounds with modifications at the sn-3 carbon
WO2004062586A2 (en) *	2003-01-09	2004-07-29	Zeneus Pharma Limited	Antineoplastic ether lipid compounds
WO2004065719A2 (en) *	2003-01-16	2004-08-05	Hunter Douglas Inc.	Covering for architectural surfaces and method of forming and applying same
EP2308879A1 (en)	2004-04-02	2011-04-13	OSI Pharmaceuticals, Inc.	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
PT1827379E (pt) *	2004-10-19	2011-03-23	Max Planck Gesellschaft	Formulações contendo alquilfosfocolinas usando novos portadores de carga negativa
JP5382974B2 (ja) *	2005-03-11	2014-01-08	太陽化学株式会社	化粧料用組成物及び化粧料
KR100829595B1 (ko)	2006-12-11	2008-05-14	한국화학연구원	당이 결합된 인지질로 수식된 리포솜 및 이의 제조방법
DK2536414T3 (en)	2010-02-18	2016-10-03	Inserm (Institut Nat De La Santé Et De La Rech Médicale)	METHOD FOR PREVENTING cancer metastasis
ES2836113T3 (es)	2016-12-14	2021-06-24	Beijing Showby Pharmaceutical Co Ltd	Clase de compuestos bifuncionales con estructura de sal de amonio cuaternario

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2009343C3 (de) *	1970-02-27	1980-10-23	Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen	Verwendung von Lysolecithinen als immunologische Adjuvantien
GB2046092B (en) *	1979-03-05	1983-11-02	Toyama Chemical Co Ltd	Pharmaceutical composition containing a lysophospholid and a phospholipid
JPS5772914A (en) *	1980-10-22	1982-05-07	Takeda Chem Ind Ltd	Antitumor agent
DE3239858A1 (de) *	1982-07-06	1984-01-12	Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen	Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden
US5169637A (en) *	1983-03-24	1992-12-08	The Liposome Company, Inc.	Stable plurilamellar vesicles
US4983397A (en) *	1985-08-19	1991-01-08	Board Of Regents, University Of Texas System	Pharmaceutical compositions consisting of acylated phospholipids
US5260284A (en) *	1987-02-17	1993-11-09	Board Of Regents, The University Of Texas System	Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy
US4965391A (en) *	1987-10-23	1990-10-23	The University Of Michigan	Radioiodinated phospholipid ether analogues
US5077057A (en) *	1989-04-05	1991-12-31	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
DE4132345A1 (de) *	1991-09-27	1993-04-01	Max Planck Gesellschaft	Ether-lysolecithine und alkylphosphocholine in liposomen
DE69519802T2 (de) *	1994-10-14	2001-04-19	The Liposome Co.,Inc.	Etherlipid-liposomen und deren therapeutische verwendung

1996
- 1996-10-15 US US08/720,997 patent/US5932242A/en not_active Expired - Fee Related
1997
- 1997-10-15 JP JP10518533A patent/JP2001502332A/ja not_active Ceased
- 1997-10-15 WO PCT/US1997/018546 patent/WO1998016200A1/en not_active Ceased
- 1997-10-15 IL IL12947397A patent/IL129473A0/xx unknown
- 1997-10-15 BR BR9712329-3A patent/BR9712329A/pt not_active Application Discontinuation
- 1997-10-15 TR TR1999/00799T patent/TR199900799T2/xx unknown
- 1997-10-15 HU HU0000523A patent/HUP0000523A3/hu unknown
- 1997-10-15 KR KR10-1999-7003214A patent/KR100512689B1/ko not_active Expired - Fee Related
- 1997-10-15 NZ NZ335125A patent/NZ335125A/xx unknown
- 1997-10-15 CN CN97180612A patent/CN1088582C/zh not_active Expired - Fee Related
- 1997-10-15 EP EP97910107A patent/EP0966266A4/en not_active Withdrawn
- 1997-10-15 PL PL97332696A patent/PL190711B1/pl not_active IP Right Cessation
- 1997-10-15 CA CA002268841A patent/CA2268841A1/en not_active Abandoned
- 1997-10-15 US US08/950,773 patent/US6017557A/en not_active Expired - Fee Related
- 1997-10-15 AU AU47567/97A patent/AU722092B2/en not_active Ceased
- 1997-10-15 CZ CZ991317A patent/CZ131799A3/cs unknown
- 1997-10-15 SK SK493-99A patent/SK283817B6/sk unknown
1999
- 1999-04-14 NO NO991770A patent/NO991770L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR100512689B1 (ko)	2005-09-07
HUP0000523A3 (en)	2000-10-30
NZ335125A (en)	1999-11-29
JP2001502332A (ja)	2001-02-20
AU722092B2 (en)	2000-07-20
AU4756797A (en)	1998-05-11
HK1024638A1 (en)	2000-10-20
EP0966266A1 (en)	1999-12-29
WO1998016200A1 (en)	1998-04-23
CN1240348A (zh)	2000-01-05
NO991770L (no)	1999-06-09
CA2268841A1 (en)	1998-04-23
PL190711B1 (pl)	2005-12-30
IL129473A0 (en)	2000-02-29
NO991770D0 (no)	1999-04-14
PL332696A1 (en)	1999-09-27
CN1088582C (zh)	2002-08-07
HUP0000523A2 (hu)	2000-09-28
TR199900799T2 (xx)	1999-07-21
SK49399A3 (en)	1999-11-08
EP0966266A4 (en)	2006-01-11
BR9712329A (pt)	1999-08-31
US5932242A (en)	1999-08-03
CZ131799A3 (cs)	1999-08-11
KR20000049128A (ko)	2000-07-25
US6017557A (en)	2000-01-25

Publication	Publication Date	Title
US6007839A (en)	1999-12-28	Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5762958A (en)	1998-06-09	Multilipid component ether lipid liposomes
Johnston et al.	2007	Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin
EP0742789B1 (en)	2000-08-30	Pharmaceutically active compounds and liposomes, and methods of use therof
US20090041835A1 (en)	2009-02-12	Method of inhibiting leakage of drug encapsulated in liposomes
US5942246A (en)	1999-08-24	Etherlipid containing multiple lipid liposomes
AU722092B2 (en)	2000-07-20	Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof
AU2012222891A1 (en)	2013-09-19	Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
EP1448165A2 (en)	2004-08-25	Lipid carrier compositions and methods for improved drug retention
DE60105977T2 (de)	2006-02-23	Auf lipiden basierende systeme zur arzneistoffabgabe
US6667053B1 (en)	2003-12-23	D and L etherlipid stereoisomers and liposomes
US5965159A (en)	1999-10-12	Etherlipid-containing multiple lipid liposomes
Chemin et al.	2009	Supramolecular organization of S12363-liposomes prepared with two different remote loading processes
HK1024638B (en)	2003-05-02	A lipid-based carrier having a lamellar lipid component for treatment of various disorders, compositions and uses thereof
USRE39042E1 (en)	2006-03-28	Etherlipid-containing multiple lipid liposomes
Ickenstein	2003	Triggered drug release from thermosemsitive liposomes
Chang	1995	Interaction and entrapment of suramin and related compounds with phospholipid vesicles